FDA Bars Ranbaxy Drugs For Manufacturing Violations

Law360, New York (September 17, 2008, 12:00 AM EDT) -- The U.S. Food and Drug Administration said it has barred more than 30 drugs manufactured by Ranbaxy Laboratories Ltd. from entering the U.S. after the company failed to address serious manufacturing deficiencies at two of its plants in India.

The agency announced Tuesday it has issued an import alert for drugs manufactured at the two plants, including generic versions of the allergy treatment Claritin, cholesterol-lowering drug Zocor, and heartburn treatment Zantac.

Officials are not requiring the drugs to be pulled off the market, saying they haven't...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.